Q-omics provides the consensus-scored LINC00402 profile across patient tissues and cancer cell-line models. LINC00402 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LINC00402 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, LINC00402 RNA expression shows 19,861 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, COAD, and LSCC as cancer lineages where LINC00402 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00402 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00402 survival associations across molecular data types. LINC00402 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00402 RNA expression–survival associations across cancer types. High LINC00402 expression shows favorable associations in HNSC, SKCM, LIHC, LUAD, CESC and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for LINC00402 RNA expression.
This table summarizes LINC00402 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00402. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00402 shows lower tumor expression in COAD, LIHC, BLCA and CHOL and higher tumor expression in BRCA and PRAD. The COAD box plot shows higher LINC00402 RNA expression in normal versus tumor tissue (log2 FC = −0.288, t-test p < 0.001).
This table shows molecular features associated with LINC00402 in patient tissues and cancer cell lines. In patient samples, LINC00402 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
